These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 11766253)
1. A pharmacokinetic-dynamic explanation of the rapid onset-offset of rapacuronium. Proost JH; Wright PM Eur J Anaesthesiol Suppl; 2001; 23():83-9. PubMed ID: 11766253 [TBL] [Abstract][Full Text] [Related]
2. A pharmacodynamic explanation for the rapid onset/offset of rapacuronium bromide. Wright PM; Brown R; Lau M; Fisher DM Anesthesiology; 1999 Jan; 90(1):16-23. PubMed ID: 9915308 [TBL] [Abstract][Full Text] [Related]
6. Rapacuronium: first experience in clinical practice. Bartkowski RR; Witkowski TA Eur J Anaesthesiol Suppl; 2001; 23():90-3. PubMed ID: 11766254 [TBL] [Abstract][Full Text] [Related]
7. Effects on laryngeal muscles and intubating conditions with new generation muscle relaxants. Meistelman C Acta Anaesthesiol Belg; 1997; 48(1):11-4. PubMed ID: 9099303 [No Abstract] [Full Text] [Related]
8. Rapacuronium bromide: a review of its use in anaesthetic practice. Onrust SV; Foster RH Drugs; 1999 Nov; 58(5):887-918. PubMed ID: 10595867 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488). Schiere S; Proost JH; Schuringa M; Wierda JM Anesth Analg; 1999 Mar; 88(3):640-7. PubMed ID: 10072020 [TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic modeling of vecuronium-induced twitch depression. Rapid plasma-effect site equilibration explains faster onset at resistant laryngeal muscles than at the adductor pollicis. Fisher DM; Szenohradszky J; Wright PM; Lau M; Brown R; Sharma M Anesthesiology; 1997 Mar; 86(3):558-66. PubMed ID: 9066321 [TBL] [Abstract][Full Text] [Related]
13. Effect of renal failure and cirrhosis on the pharmacokinetics and neuromuscular effects of rapacuronium administered by bolus followed by infusion. Fisher DM; Dempsey GA; Atherton DP; Brown R; Abengochea A; Hunter JM Anesthesiology; 2000 Dec; 93(6):1384-91. PubMed ID: 11149430 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. Duvaldestin P; Slavov V; Rebufat Y Anesthesiology; 1999 Nov; 91(5):1305-10. PubMed ID: 10551581 [TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of rapacuronium bromide, a new short-acting neuromuscular blocking agent. Larijani GE; Zafeiridis A; Goldberg ME Pharmacotherapy; 1999 Oct; 19(10):1118-22. PubMed ID: 10512060 [TBL] [Abstract][Full Text] [Related]
17. Influence of renal failure on the pharmacokinetics and neuromuscular effects of a single dose of rapacuronium bromide. Szenohradszky J; Caldwell JE; Wright PM; Brown R; Lau M; Luks AM; Fisher DM Anesthesiology; 1999 Jan; 90(1):24-35. PubMed ID: 9915309 [TBL] [Abstract][Full Text] [Related]
18. Neuromuscular blocking drugs for the new millennium: current practice, future trends--comparative pharmacology of neuromuscular blocking drugs. Donati F Anesth Analg; 2000 May; 90(5 Suppl):S2-S6. PubMed ID: 10809511 [No Abstract] [Full Text] [Related]
19. Rapacuronium for neuromuscular blockade in two myasthenic patients undergoing trans-sternal thymectomy. Baraka AS; Taha SK; Rizk MS; Rachid-Chehab I; Jalbout MI; Bizri SH Eur J Anaesthesiol; 2001 Nov; 18(11):778-80. PubMed ID: 11580788 [No Abstract] [Full Text] [Related]
20. Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. Reynolds LM; Infosino A; Brown R; Hsu J; Fisher DM Anesthesiology; 2000 Feb; 92(2):376-86. PubMed ID: 10691223 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]